Latest Commercialization News

Syrah Resources and Tesla have agreed to extend the cure date for an alleged default under their offtake agreement to March 2026, buying time to resolve ongoing qualification issues at Syrah’s Vidalia facility.

Iondrive Limited appoints Lewis Utting as CEO to spearhead the transition from technology development to commercial execution of its IONSolv™ platform, while refreshing its board with new expertise.

Rimfire Pacific Mining reveals a significant gold-antimony mineralised corridor at its Windy Ridge prospect, reigniting interest in a largely overlooked Broken Hill asset with strategic critical minerals potential.

PolyNovo reports a robust 26% increase in group sales for 1H FY26, driven by strong U.S. market expansion and a near tripling of NovoSorb MTX sales. The company also completes a new manufacturing facility, positioning itself for sustained growth.

AXP Energy reports promising early production from its Charlie #1 well in Oklahoma and plans to increase output by installing a larger pumpjack.

Tetratherix has inked a global exclusive distribution agreement with healthcare giant Henry Schein, paving the way for its first bone regeneration product, Tegenix, to enter major markets in 2026. Concurrently, the company has begun building an advanced manufacturing facility to meet expected global demand.

Solstice Minerals has ramped up its drilling program at the Nanadie Copper-Gold Project, aiming to significantly grow its existing resource, while advancing gold exploration at Yarri with strong assay anticipation.

Talga Group has entered a strategic development agreement with German battery innovator V4Smart to co-develop high-performance graphite anodes for fast-charging lithium-ion batteries, aiming for commercial readiness by 2027.

Osteopore Limited has inked an exclusive collaboration with Majeton to commercialise its cutting-edge 3D-printed bioresorbable implants across China, Hong Kong, and Macau, unlocking significant growth potential in the region.

Northern Minerals reports encouraging preliminary metallurgical results from blending the Dazzler deposit with Wolverine ore, potentially expanding feed supply and optimising the Browns Range Heavy Rare Earths Project.

Zelira Therapeutics has raised nearly US$33 million from ThirdGate Capital to advance its HOPE® 1 drug targeting autism-related Phelan-McDermid Syndrome through FDA clinical trials. This funding milestone sets the stage for pivotal regulatory progress in the US.

Bass Oil reported steady December production with a notable gas sales agreement for the Vanessa field, signaling a strategic shift towards gas commercialization.